EDGEWISE THERAPEUTICS INC
EWTXNASDAQ🏆 #1379 by market capEarnings Nov 5US Equity
$38.86▼ $1.63 (−4.03%)
Latest quoteTrack EWTX
Get earnings, price moves & breaking news on Telegram
24h▼ 4.0%
7d▼ 2.8%
14d▲ 1.8%
30d▼ 0.8%
ytd▲ 56.7%
1y▲ 138.1%
🏦Market Cap
$4.18B
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
44
Weak
EDGEWISE THERAPEUTICS INC
EWTXAnalyst Ratings
Price
$38.86
Total
11
Raised
0
Lowered
1
Avg PT
$53.10
H / L
$66 / $36
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
HC Wainwright & Co. | Reiterated | Buy | 2026-09-21 | — | — |
JP Morgan | Reiterated | Overweight | 2026-08-20 | — | — |
Goldman Sachs | Reiterated | Neutral | 2026-08-11 | $36.00 | −7.40% |
Evercore ISI Group | Reiterated | Outperform | 2026-07-20 | — | — |
Guggenheim | Reiterated | Buy | 2026-07-06 | $51.00 | +31.20% |
RBC Capital | Reiterated | Outperform | 2026-06-17 | $59.00 | +51.80% |
Wedbush | Reiterated | Outperform | 2026-06-02 | $52.00 | +33.80% |
Scotiabank | Downgraded | Sector Outperform → Sector Perform | 2025-04-03 | $50.00 | +28.70% |
Piper Sandler | Reiterated | Overweight | 2025-04-02 | $51.00 | +31.20% |
Truist Securities | Reiterated | Buy | 2024-11-27 | — | — |
SVB Leerink | Reiterated | Outperform | 2022-05-12 | — | — |
Institution
HC Wainwright & Co.
Reiterated · Buy · 2026-09-21
—
—
JP Morgan
Reiterated · Overweight · 2026-08-20
—
—
Goldman Sachs
Reiterated · Neutral · 2026-08-11
$36.00
−7.40%
Evercore ISI Group
Reiterated · Outperform · 2026-07-20
—
—
Guggenheim
Reiterated · Buy · 2026-07-06
$51.00
+31.20%
RBC Capital
Reiterated · Outperform · 2026-06-17
$59.00
+51.80%
Wedbush
Reiterated · Outperform · 2026-06-02
$52.00
+33.80%
Scotiabank
Downgraded · Sector Outperform → Sector Perform · 2025-04-03
$50.00
+28.70%
Piper Sandler
Reiterated · Overweight · 2025-04-02
$51.00
+31.20%
Truist Securities
Reiterated · Buy · 2024-11-27
—
—
SVB Leerink
Reiterated · Outperform · 2022-05-12
—
—
One row per institution · price target from the firm's latest published target